BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12183426)

  • 1. Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesis.
    Machover D; Zittoun J; Saffroy R; Broët P; Giraudier S; Magnaldo T; Goldschmidt E; Debuire B; Orrico M; Tan Y; Mishal Z; Chevallier O; Tonetti C; Jouault H; Ulusakarya A; Tanguy ML; Metzger G; Hoffman RM
    Cancer Res; 2002 Aug; 62(16):4685-9. PubMed ID: 12183426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Methioninase as a DNA Demethylation Agent.
    Hoffman RM; Machover D
    Methods Mol Biol; 2019; 1866():279-284. PubMed ID: 30725424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic synergism of methioninase in combination with 5-fluorouracil and folinic acid.
    Machover D; Zittoun J; Broët P; Metzger G; Orrico M; Goldschmidt E; Schilf A; Tonetti C; Tan Y; Delmas-Marsalet B; Luccioni C; Falissard B; Hoffman RM
    Biochem Pharmacol; 2001 Apr; 61(7):867-76. PubMed ID: 11274973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment.
    Miki K; Al-Refaie W; Xu M; Jiang P; Tan Y; Bouvet M; Zhao M; Gupta A; Chishima T; Shimada H; Makuuchi M; Moossa AR; Hoffman RM
    Cancer Res; 2000 May; 60(10):2696-702. PubMed ID: 10825143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
    Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM
    Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival efficacy of the combination of the methioninase gene and methioninase in a lung cancer orthotopic model.
    Miki K; Xu M; An Z; Wang X; Yang M; Al-Refaie W; Sun X; Baranov E; Tan Y; Chishima T; Shimada H; Moossa AR; Hoffman RM
    Cancer Gene Ther; 2000 Feb; 7(2):332-8. PubMed ID: 10770644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
    Yang Z; Wang J; Lu Q; Xu J; Kobayashi Y; Takakura T; Takimoto A; Yoshioka T; Lian C; Chen C; Zhang D; Zhang Y; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Sep; 64(18):6673-8. PubMed ID: 15374983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase.
    Yoshioka T; Wada T; Uchida N; Maki H; Yoshida H; Ide N; Kasai H; Hojo K; Shono K; Maekawa R; Yagi S; Hoffman RM; Sugita K
    Cancer Res; 1998 Jun; 58(12):2583-7. PubMed ID: 9635582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy.
    Tan Y; Xu M; Tan X; Tan X; Wang X; Saikawa Y; Nagahama T; Sun X; Lenz M; Hoffman RM
    Protein Expr Purif; 1997 Mar; 9(2):233-45. PubMed ID: 9056489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients.
    Tan Y; Zavala J; Han Q; Xu M; Sun X; Tan X; Tan X; Magana R; Geller J; Hoffman RM
    Anticancer Res; 1997; 17(5B):3857-60. PubMed ID: 9427792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy.
    Tan Y; Sun X; Xu M; An Z; Tan X; Han Q; Miljkovic DA; Yang M; Hoffman RM
    Protein Expr Purif; 1998 Feb; 12(1):45-52. PubMed ID: 9473456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate.
    Yang Z; Sun X; Li S; Tan Y; Wang X; Zhang N; Yagi S; Takakura T; Kobayashi Y; Takimoto A; Yoshioka T; Suginaka A; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Aug; 64(16):5775-8. PubMed ID: 15313919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation.
    Sun X; Yang Z; Li S; Tan Y; Zhang N; Wang X; Yagi S; Yoshioka T; Takimoto A; Mitsushima K; Suginaka A; Frenkel EP; Hoffman RM
    Cancer Res; 2003 Dec; 63(23):8377-83. PubMed ID: 14678999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
    Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
    Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.
    Geoffroy FJ; Allegra CJ; Sinha B; Grem JL
    Oncol Res; 1994; 6(12):581-91. PubMed ID: 7787251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad selective efficacy of rMETase and PEG-rMETase on cancer cells in vitro.
    Tan Y; Xu M; Hoffman RM
    Anticancer Res; 2010 Mar; 30(3):793-8. PubMed ID: 20392998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad selective efficacy of recombinant methioninase and polyethylene glycol-modified recombinant methioninase on cancer cells In Vitro.
    Tan Y; Xu M; Hoffman RM
    Anticancer Res; 2010 Apr; 30(4):1041-6. PubMed ID: 20530407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Murakami T; Li S; Han Q; Tan Y; Kiyuna T; Igarashi K; Kawaguchi K; Hwang HK; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Hiroshima Y; Lwin TM; DeLong JC; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
    Oncotarget; 2017 May; 8(22):35630-35638. PubMed ID: 28404944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of constitutive pericentromeric heterochromatin in lymphocytes of cancer patients and lymphocytes exposed to 5-azacytidine is associated with DNA-hypomethylation.
    Shvachko LP
    Exp Oncol; 2008 Sep; 30(3):230-4. PubMed ID: 18806747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.